NYSEARCA:VNRX - NYSE Arca - US9286611077 - Common Stock - Currency: USD
0.5389
+0.01 (+2.12%)
The current stock price of VNRX is 0.5389 USD. In the past month the price increased by 7.76%. In the past year, price decreased by -20.74%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ALC | ALCON INC | 28.48 | 42.69B | ||
COO | COOPER COS INC/THE | 17.24 | 13.38B | ||
ALGN | ALIGN TECHNOLOGY INC | 19.2 | 12.99B | ||
SOLV | SOLVENTUM CORP | 12.48 | 12.85B | ||
MMSI | MERIT MEDICAL SYSTEMS INC | 26.5 | 5.59B | ||
LNTH | LANTHEUS HOLDINGS INC | 11.74 | 5.38B | ||
BLCO | BAUSCH + LOMB CORP | 23.96 | 4.06B | ||
HAE | HAEMONETICS CORP/MASS | 15.24 | 3.35B | ||
ICUI | ICU MEDICAL INC | 18.7 | 3.21B | ||
XRAY | DENTSPLY SIRONA INC | 9.46 | 3.17B | ||
UFPT | UFP TECHNOLOGIES INC | 29.24 | 1.84B | ||
NEOG | NEOGEN CORP | 15.79 | 1.30B |
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 85 full-time employees. The company went IPO on 2015-02-06. The firm is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
VOLITIONRX LTD
1489 West Warm Springs Road, Suite 110
Henderson NEVADA 78738 US
CEO: Cameron Reynolds
Employees: 85
Phone: 16466501351
The current stock price of VNRX is 0.5389 USD. The price increased by 2.12% in the last trading session.
The exchange symbol of VOLITIONRX LTD is VNRX and it is listed on the NYSE Arca exchange.
VNRX stock is listed on the NYSE Arca exchange.
10 analysts have analysed VNRX and the average price target is 3.22 USD. This implies a price increase of 497.16% is expected in the next year compared to the current price of 0.5389. Check the VOLITIONRX LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
VOLITIONRX LTD (VNRX) has a market capitalization of 55.52M USD. This makes VNRX a Micro Cap stock.
VOLITIONRX LTD (VNRX) currently has 85 employees.
VOLITIONRX LTD (VNRX) has a support level at 0.48 and a resistance level at 0.58. Check the full technical report for a detailed analysis of VNRX support and resistance levels.
The Revenue of VOLITIONRX LTD (VNRX) is expected to grow by 346.89% in the next year. Check the estimates tab for more information on the VNRX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
VNRX does not pay a dividend.
VOLITIONRX LTD (VNRX) will report earnings on 2025-08-12, after the market close.
VOLITIONRX LTD (VNRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.27).
The outstanding short interest for VOLITIONRX LTD (VNRX) is 0.42% of its float. Check the ownership tab for more information on the VNRX short interest.
ChartMill assigns a technical rating of 3 / 10 to VNRX. When comparing the yearly performance of all stocks, VNRX is a bad performer in the overall market: 81.07% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to VNRX. Both the profitability and financial health of VNRX have multiple concerns.
Over the last trailing twelve months VNRX reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS increased by 41.3% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -281.97% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to VNRX. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 57.23% and a revenue growth 346.89% for VNRX